Exercise Program for Lymphoma Patients on Chemotherapy
This study, called iSTAND, is looking at whether a 12-week exercise program can help lymphoma patients who are starting R-CHOP or POLA-R-CHP chemotherapy. The program involves reminder prompts, counseling, and activities like walking, cycling, and resistance band exercises, done at home and in the clinic with an exercise trainer. The main goal is to see if this exercise program is practical for patients and if it can improve heart health and reduce side effects from chemotherapy. We are looking for about 24 newly diagnosed lymphoma patients, aged 18 and older, to join this study. The study's status is currently unclear.
- Study design
- This is an interventional study with about 24 participants. You would be randomly assigned to either the exercise program group or a usual care group.
- What's involved
- You would participate in the study for about 3 months, which includes screening, fitness and physical health assessments, blood tests, and questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- Retention will be measured at 13 weeks after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Christina Dieli-Conwright, MD, PhD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Intervention Completion Rate (Feasibility)12 weeks
Intervention feasibility is defined as: 1) A participant completes ≥70% of the supervised activity breaks on at least 3 out of the 4 infusion appointments. 2) A participant completes ≥70% of the prescribed home-based resistance activity breaks on at least 48 days out of the possible 68 days (12 week) intervention (excluding the 4 infusion days and 1 rest day per week) (i.e., meet interrupting sedentary behavior goals across at least 70% of the intervention). 3) A participant completes ≥70% of the prescribed home-based step goals (i.e., \>250 steps per hour) on at least 48 days out of the possible 68 days (12 week) intervention (excluding the 4 infusion days and 1 rest day per week) (i.e., meet interrupting sedentary behavior goals across at least 70% of the intervention).
- Refusal Rate12 weeks
Defined as ≤50% of eligible screened participants refuse to complete intervention.
- Retention Rate13 weeks
Retention of consented participants to study end is ≥70%.
- Acceptability of Intervention Measure (AIM) Scale13 weeks
Assessed by the Acceptability of the Intervention Measures, a 4-item measure rated on a 5-point Likert scale with answers ranging from "Completely disagree" to "Completely agree." A total scores range is 4 to 20 with a higher score indicating greater acceptability. The intervention will be deemed acceptable by participants if ≥70% of participants have a mean score ≥ 4 on the AIM.
- Acceptability Exit Survey13 weeks
The intervention will be deemed acceptable by participants if 1) ≥70% of participants report "agree" or "strongly agree" to the prompt "Participation in this study helped me reduce my daily sedentary time" and 2) ≥70% of participants report "probably" or "yes" to the prompt "I would recommend this program to other patients being treated for cancer."